Sarcopenia Detection
TL;DR
Sarcopenia is a progressive skeletal muscle disorder diagnosed in three EWGSOP2 stages: probable (low grip strength), confirmed (+low muscle quantity/quality on DXA), and severe (+low physical performance). For Vitals users on Retatrutide, the primary concern is accelerated age-related muscle loss during GLP-1 therapy — not clinical sarcopenia per se, but the 21–45% lean mass fraction of weight lost on GLP-1 agents, confounded by unresolved biomarkers and consumer BIA inaccuracy. DXA is the gold standard for body composition; consumer smart scales are not. iPhone gait speed is the most validated wearable measurement for functional decline.
Why it matters for Vitals
Ben is on Retatrutide (GLP-1/GIP/GCGR triple agonist). The practical detection questions are:
- Is muscle being lost faster than it should be? BIA trend + grip strength trend answer this
- When does BIA trend warrant a DEXA referral? >5% ALM loss in 30 days on GLP-1 therapy
- Which biomarkers are trustworthy vs. confounded? Cystatin C > creatinine; IGF-1 only with AM fasting draws
- What can wearables actually measure? iPhone gait speed (yes); Apple Watch muscle mass (no); smartwatch grip strength (false claim)
- When does coaching escalate to clinical referral? Tier 3 triggers: gait speed ≤0.8 m/s, grip <27 kg (men), BIA ALM loss >5%/30 days
This hub is the entry point. Child notes provide depth on criteria, biomarkers, GLP-1 body composition, gait speed, and coaching protocol.
Key facts
| Stage | Criterion | Measurement |
|---|---|---|
| Probable sarcopenia | Low muscle strength | Grip strength <27 kg (men) / <16 kg (women); or 5-rep chair stand |
| Confirmed sarcopenia | + Low muscle quantity/quality | DXA ALMI <7.0 kg/m² (men) / <5.5 kg/m² (women) |
| Severe sarcopenia | + Low physical performance | Gait speed ≤0.8 m/s; SPPB ≤8; Timed Up-and-Go ≥20 s |
EWGSOP2: PMID:30878586
Body composition methods
DXA: Gold standard for appendicular lean mass (ALM). LSC for individual change detection is 3.85–19.4% — meaning real changes of <4–19% can be missed in a single patient. Use for baseline and Tier 3 referral; not for frequent monitoring.
BIA: Acceptable proxy when DXA unavailable. Consumer foot-to-foot BIA errors up to ~10 kg (LoA −9.5 to +3.9 kg). Withings Body Scan (segmental multi-frequency BIA): bias −0.60 ± 1.21 kg vs. DEXA — minimum acceptable device for Vitals coaching. See Sarcopenia Diagnostic Criteria for detailed BIA accuracy data.
Blood biomarkers
- Cystatin C: preferred over creatinine for kidney-independent muscle health monitoring; stable production rate unaffected by diet or activity
- Creatinine: confounded during GLP-1 therapy by renal hemodynamic effects and changing muscle mass; insufficient alone
- IGF-1: ~30% diurnal variation — morning fasting draws only; useful as trend monitor, not single value
- 3-methylhistidine: not practical for coaching (requires 5-day creatine-free diet + 24h urine)
- See Muscle Health Biomarkers for detailed accuracy data, Sarcopenia Index formula, and reference ranges
Wearable facts
- Apple Watch cannot measure muscle mass, grip strength, or screen for sarcopenia — no validated sensor or algorithm exists (PMID:38806267; 82 studies, 430,052 participants)
- iPhone Health gait speed: ICC >0.96 vs. APDM gold standard (PMID:PMCID:PMC10067003) — directly validated for gait speed
- Apple Watch HRV: deep-breathing SDNN, not standard nocturnal rMSSD; different metric from what sarcopenia-HRV research uses
- See Wearable Gait Speed for detailed validation and clinical thresholds
GLP-1 lean mass
- 21–45% of total weight lost on GLP-1 therapy comes from lean mass (PMID:40289060; STEP 1 DEXA: ~45%)
- Fracture risk +11% in adults ≥65 on GLP-1 vs. other diabetes meds (PMID:41665888); hip BMD −2.6%, lumbar spine BMD −2.1% within 1 year (PMID:41655226)
- Semaglutide accelerates sarcopenia in older adults with T2D over 24 months (PMID:40631351)
- See GLP-1 Body Composition for mechanism, risk populations, and preservation strategies
Coaching tiers
Green / Yellow / Red tier system based on gait speed, grip strength, BIA trends, HRV trends, and protein intake. See Sarcopenia Coaching Protocol.
What stays inside this hub
- Detailed biomarker PK tables (see Muscle Health Biomarkers)
- Full DXA LSC and BIA accuracy tables (see Sarcopenia Diagnostic Criteria)
- Full coaching tier decision logic (see Sarcopenia Coaching Protocol)
- Algorithm hooks and pseudocode (see individual satellite notes)
Related notes
Satellite notes
- Sarcopenia Diagnostic Criteria — EWGSOP2 stages, DXA vs. BIA, grip strength, gait speed cut-offs, LSC values
- Muscle Health Biomarkers — cystatin C, creatinine, IGF-1, 3MH; Sarcopenia Index formula and accuracy
- GLP-1 Body Composition — lean mass fraction, safety signals, high-risk populations, preservation protocol
- Wearable Gait Speed — iPhone vs. Apple Watch, validation data, clinical thresholds
- Sarcopenia Coaching Protocol — Green/Yellow/Red tier system, action triggers, DEXA referral criteria
Related mechanism notes
- mTOR AMPK Muscle Catabolism — muscle protein synthesis/suppression during caloric deficit
- ActRII Myostatin Pathway — myostatin/activin axis; bimagrumab as only pharmacologic with human lean-gain evidence
- GLP-1 Muscle Preservation — GLP-1 lean mass effects, preservation evidence; distinct from this detection-focused hub
- Resistance Training for Longevity — the anchor intervention for muscle preservation
Related substance notes
- Retatrutide — Ben’s primary GLP-1 agent; lean mass fraction expected at the upper end of the GLP-1 class range due to GCGR activation
- GLP-1 Muscle Preservation — full preservation evidence review; notes that resistance training + protein are the only evidence-backed strategies
Related biometrics notes
- HRV — HRV decline >30% from 90-day baseline sustained 2+ weeks is a coaching check-in trigger; not a sarcopenia diagnostic
- Blood Biomarker Optimization — broader biomarker tracking framework; cystatin C and IGF-1 listed there
MOC / maps
- Vitals Knowledge Map — top-level index
- Peptides MOC — Retatrutide and related peptides